The immediate priority is to determine whether there is a role for HDC in the therapy of breast cancer and other solid tumours. Developmental work is needed to address other important questions e.g. role of late intensification versus primary high dose, graft manipulation, and purging. Newer biological anti-cancer agents may produce maximum impact in the setting of minimal disease, and the proven ability of HDC to produce frequent CRs suggests future investigations may involve both these modalities of treatment.
Was this article helpful?